LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Search

Ligand Pharmaceuticals Inc

Închisă

SectorSănătate

200.01 -0.21

Rezumat

Modificarea prețului

24h

Curent

Minim

197.8

Maxim

207.35

Indicatori cheie

By Trading Economics

Venit

47M

4.8M

Vânzări

70M

115M

P/E

Medie Sector

92.606

105.69

Marjă de profit

4.198

Angajați

68

EBITDA

103M

62M

Recomandări

By TipRanks

Recomandări

Puternic Cumpărare

Prognoză pe 12 luni

+18.65% upside

Statistici piață

By TradingEconomics

Capitalizare de piață

1.5B

4.1B

Deschiderea anterioară

200.22

Închiderea anterioară

200.01

Sentimentul știrilor

By Acuity

28%

72%

70 / 374 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

17 nov. 2025, 18:59 UTC

Principalele dinamici ale pieței

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 nov. 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 nov. 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 nov. 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 nov. 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 nov. 2025, 22:06 UTC

Achiziții, Fuziuni, Preluări

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 nov. 2025, 22:02 UTC

Câștiguri

Trip.com Group 3Q Rev $2.6B >TCOM

17 nov. 2025, 22:02 UTC

Câștiguri

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 nov. 2025, 22:02 UTC

Câștiguri

Trip.com Group 3Q EPS $4.02 >TCOM

17 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 nov. 2025, 21:40 UTC

Câștiguri

James Hardie Industries 2Q Adj EPS 26c >JHX

17 nov. 2025, 21:40 UTC

Câștiguri

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 nov. 2025, 21:39 UTC

Câștiguri

James Hardie Industries 2Q Sales $1.29B >JHX

17 nov. 2025, 21:38 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 21:38 UTC

Câștiguri

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 nov. 2025, 21:10 UTC

Câștiguri

XP Inc. 3Q EPS BRL2.47 >XP

17 nov. 2025, 21:10 UTC

Câștiguri

XP Inc. 3Q Rev BRL4.67B >XP

17 nov. 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 nov. 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 nov. 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 nov. 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 nov. 2025, 19:16 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 18:20 UTC

Achiziții, Fuziuni, Preluări

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 nov. 2025, 16:45 UTC

Achiziții, Fuziuni, Preluări

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 nov. 2025, 16:16 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 nov. 2025, 16:15 UTC

Câștiguri

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 nov. 2025, 15:40 UTC

Achiziții, Fuziuni, Preluări

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 nov. 2025, 15:22 UTC

Achiziții, Fuziuni, Preluări

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 nov. 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Comparație

Modificare preț

Ligand Pharmaceuticals Inc Așteptări

Obiectiv de preț

By TipRanks

18.65% sus

Prognoză pe 12 luni

Medie 238.33 USD  18.65%

Maxim 275 USD

Minim 220 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruLigand Pharmaceuticals Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

6

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

102.5 / 109.24Suport & Rezistență

Termen scurt

Strong Bearish Evidence

Termen mediu

Very Strong Bearish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

70 / 374 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat